Home/Filings/4/0001144204-18-049522
4//SEC Filing

Almon Einat Brill 4

Accession 0001144204-18-049522

CIK 0001006281other

Filed

Sep 13, 8:00 PM ET

Accepted

Sep 14, 4:31 PM ET

Size

6.2 KB

Accession

0001144204-18-049522

Insider Transaction Report

Form 4
Period: 2018-09-13
Almon Einat Brill
VP, Product Development
Transactions
  • Award

    Stock Options (Right to Buy)

    2018-09-13+700,000700,000 total
    Exercise: $0.56Exp: 2028-09-13Common Stock (700,000 underlying)
Footnotes (2)
  • [F1]The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
  • [F2]Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025.

Issuer

Protalix BioTherapeutics, Inc.

CIK 0001006281

Entity typeother

Related Parties

1
  • filerCIK 0001385116

Filing Metadata

Form type
4
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 4:31 PM ET
Size
6.2 KB